Compare Neurocrine Biosciences Inc (NBIX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Xcel Energy Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Xcel Energy Inc trades at $76.24 (market cap $48.02B). The key difference: Xcel Energy Inc is far larger — about 3× Neurocrine Biosciences Inc's market cap, and Xcel Energy Inc pays a 3.08% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | XEL | |
|---|---|---|
Market Cap | $15.77B | $48.02B |
Sector | Health | Utilities |
52-Week High | $185.50 | $83.91 |
52-Week Low | $123.10 | $72.05 |
Enterprise Value | $15.78B | $86.33B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
XEL trades at $76.88, up 1.53% on the day, with a bearish technical signal but strong analyst consensus. Recent Q2 2026 earnings beat estimates at $0.93 per share. The company maintains solid profitability with a 15.28% net income margin and is executing a $70B+ capital investment plan through 2030 to drive growth. Dividend payments remain consistent at $0.59 quarterly.
Outlook is positive with a $92 consensus price target, though risks include high capital expenditures, regulatory scrutiny from wildfire lawsuits, and rising interest rates. The stock offers stable income and growth potential but faces execution and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
